Sei Investments Co. Has $933,000 Holdings in Trevi Therapeutics, Inc. $TRVI

Sei Investments Co. trimmed its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 47.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 78,222 shares of the company’s stock after selling 69,719 shares during the period. Sei Investments Co. owned 0.06% of Trevi Therapeutics worth $933,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Alliancebernstein L.P. increased its holdings in Trevi Therapeutics by 19,064.5% in the 2nd quarter. Alliancebernstein L.P. now owns 4,281,355 shares of the company’s stock worth $23,419,000 after purchasing an additional 4,259,015 shares in the last quarter. Rubric Capital Management LP grew its holdings in shares of Trevi Therapeutics by 88.0% during the second quarter. Rubric Capital Management LP now owns 8,531,860 shares of the company’s stock worth $46,669,000 after purchasing an additional 3,993,325 shares during the last quarter. Viking Global Investors LP raised its holdings in Trevi Therapeutics by 232.4% in the 3rd quarter. Viking Global Investors LP now owns 5,128,875 shares of the company’s stock valued at $46,929,000 after buying an additional 3,585,875 shares during the last quarter. Wellington Management Group LLP boosted its position in Trevi Therapeutics by 1,792.0% during the 3rd quarter. Wellington Management Group LLP now owns 3,253,888 shares of the company’s stock worth $29,773,000 after buying an additional 3,081,906 shares during the period. Finally, Marshall Wace LLP grew its holdings in Trevi Therapeutics by 95.4% during the 3rd quarter. Marshall Wace LLP now owns 4,841,751 shares of the company’s stock worth $44,302,000 after acquiring an additional 2,363,835 shares during the last quarter. Institutional investors own 95.76% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Friday, July 17th. HC Wainwright increased their price objective on Trevi Therapeutics from $21.00 to $24.00 and gave the company a “buy” rating in a report on Monday, July 20th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $40.00 target price on shares of Trevi Therapeutics in a report on Friday, August 7th. Morgan Stanley reissued an “overweight” rating and issued a $23.00 price target on shares of Trevi Therapeutics in a research note on Friday, August 7th. Finally, Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday, May 20th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $26.75.

Trevi Therapeutics Stock Performance

NASDAQ:TRVI opened at $17.73 on Thursday. Trevi Therapeutics, Inc. has a 52 week low of $6.93 and a 52 week high of $20.22. The firm’s fifty day moving average is $17.22 and its 200-day moving average is $14.18. The firm has a market cap of $2.53 billion, a P/E ratio of -52.15 and a beta of 1.03.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Thursday, August 6th. The company reported ($0.11) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.11). As a group, sell-side analysts anticipate that Trevi Therapeutics, Inc. will post -0.48 earnings per share for the current year.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.